SOPHiA GENETICS is a Swiss precision-medicine software company whose second-quarter print is the first under a new chief executive and a freshly recapitalized balance sheet. The investment debate is whether a decade-built hospital network can now convert into accelerating, self-funding growth, or whether another equity sale merely bought time. Operating momentum and dilutive financing arrived in the same quarter, and that pairing is the entire story. A reader who treats the print as a clean software inflection without the capital-structure reset is reading only half of the quarter.
The operating engine is a land-and-expand analytics platform that hospitals keep once they go live. Net dollar retention, the share of prior-year customer revenue that recurs and expands, climbed to 117 percent. United States volume and liquid-biopsy mix are lifting reported growth above analysis-count growth, which is the first real evidence that higher-value applications are changing the average ticket. The counterweight is conversion, not demand: more than half of the signed liquid-biopsy accounts have not completed implementation, so the application story is still a go-live project rather than a fully booked run-rate.
Management raised full-year revenue guidance after a mid-year follow-on that rebuilt cash. Adjusted EBITDA loss, the company measure that strips depreciation, share-based pay, litigation, and restructuring, narrowed even as reported net loss stayed roughly unchanged. Interest on the Perceptive term loan, Guardant Health legal spend, and a second-quarter workforce action sit outside that company measure and still hit cash. The next several quarters resolve whether United States go-lives and the first AstraZeneca companion-diagnostic programs turn the new cash cushion into a path that does not require another sale of shares.